528 related articles for article (PubMed ID: 27997653)
1. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
[TBL] [Abstract][Full Text] [Related]
2. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
[TBL] [Abstract][Full Text] [Related]
3. Helicase-primase inhibitor pritelivir for HSV-2 infection.
Wald A; Corey L; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Kriesel J; Fife K; Galitz L; Stoelben S; Huang ML; Selke S; Stobernack HP; Ruebsamen-Schaeff H; Birkmann A
N Engl J Med; 2014 Jan; 370(3):201-10. PubMed ID: 24428466
[TBL] [Abstract][Full Text] [Related]
4. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
[TBL] [Abstract][Full Text] [Related]
5. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
6. Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes.
Martens MG; Fife KH; Leone PA; Dix LP; Brennan CA
Infect Dis Obstet Gynecol; 2009; 2009():105376. PubMed ID: 19680456
[TBL] [Abstract][Full Text] [Related]
7. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.
Le Cleach L; Trinquart L; Do G; Maruani A; Lebrun-Vignes B; Ravaud P; Chosidow O
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009036. PubMed ID: 25086573
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.
Wald A; Selke S; Warren T; Aoki FY; Sacks S; Diaz-Mitoma F; Corey L
Sex Transm Dis; 2006 Sep; 33(9):529-33. PubMed ID: 16540883
[TBL] [Abstract][Full Text] [Related]
9. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
Johnston C; Saracino M; Kuntz S; Magaret A; Selke S; Huang ML; Schiffer JT; Koelle DM; Corey L; Wald A
Lancet; 2012 Feb; 379(9816):641-7. PubMed ID: 22225814
[TBL] [Abstract][Full Text] [Related]
10. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J
Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210
[TBL] [Abstract][Full Text] [Related]
12. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
[TBL] [Abstract][Full Text] [Related]
13. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
14. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study.
Kim HN; Wald A; Harris J; Almekinder J; Heitman C; Corey L
Sex Transm Dis; 2008 Feb; 35(2):124-8. PubMed ID: 17921912
[TBL] [Abstract][Full Text] [Related]
15. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
[TBL] [Abstract][Full Text] [Related]
16. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women.
Andrews WW; Kimberlin DF; Whitley R; Cliver S; Ramsey PS; Deeter R
Am J Obstet Gynecol; 2006 Mar; 194(3):774-81. PubMed ID: 16522412
[TBL] [Abstract][Full Text] [Related]
17. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.
Sheffield JS; Hill JB; Hollier LM; Laibl VR; Roberts SW; Sanchez PJ; Wendel GD
Obstet Gynecol; 2006 Jul; 108(1):141-7. PubMed ID: 16816068
[TBL] [Abstract][Full Text] [Related]
18. Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals.
Agyemang E; Magaret AS; Selke S; Johnston C; Corey L; Wald A
J Infect Dis; 2018 Oct; 218(11):1691-1699. PubMed ID: 30020484
[TBL] [Abstract][Full Text] [Related]
19. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial.
Abudalu M; Tyring S; Koltun W; Bodsworth N; Hamed K
Clin Infect Dis; 2008 Sep; 47(5):651-8. PubMed ID: 18637755
[TBL] [Abstract][Full Text] [Related]
20. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir.
Wald A; Zeh J; Barnum G; Davis LG; Corey L
Ann Intern Med; 1996 Jan; 124(1 Pt 1):8-15. PubMed ID: 7503497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]